Hodgkin’s Disease Treatments — EDR
Learn More About Hodgkin's Disease Extreme Drug Resistance: Chat with Us | Email Us
Extreme Drug Resistance for Hodgkin's Disease
At Cancer Treatment Centers of America (CTCA), we understand Hodgkin’s disease affects each patient differently. This is why we provide you with a customized Hodgkin’s disease treatment plan tailored to your individual needs. One of the innovative diagnostic tools we use to personalize your treatment is the Extreme Drug Resistance (EDR) Assay (or Chemoresistance).
The EDR is a highly accurate tool CTCA clinicians use to test solid Hodgkin’s disease tumors, outside of the body, for resistance to specific chemotherapeutic drugs. If a patient’s tumor cells are still able to grow after extreme exposure to a particular anti-cancer drug, then the tumor will most likely be resistance to that drug if it is administered in the body.
Thus, by testing the chemotherapy drugs outside of the body, our clinicians can determine whether the drugs will work inside the body. With this valuable information, CTCA physicians can test the effectiveness of chemotherapy drugs in advance.
The Extreme Drug Resistance Assay helps to avoid unnecessary toxicity to you, minimize costs, and allow our physicians to consider protocols for other Hodgkin’s disease treatments.
Next Topic: MRI for Hodgkin's Disease